Jürgen Kuball, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, describes the session about CAR-T regulatory issues and reimbursements that will be taking place at the 3rd European CAR T-cell Meeting. During this session, the panel will discuss how patients in Europe can get access to these novel treatments. Prof. Kuball mentions that there are many hurdles in the regulatory process, particularly when comparing between Europe and the US, where the regulatory agencies and the landscape in terms of how healthcare systems are structured are different. This interview took place during the 3rd European CAR T-cell Meeting.
Scientific co-founder and shareholder of Gadeta. Inventor on multiple patents dealing with gdT cells and their receptors as well as isolation of engineered immune cells. Research support by Novartis, Miltenyi Biotech and Gadeta.